IL6 and neutropenia: Although transient neutropenia has been observed in several studies involving patients affected by autoimmune diseases, such as RA treated with drugs targeting the IL-6 cascade, the serious infection rate in these patients did not appear to be increased, suggesting that blocking IL-6 pathways may influence the neutrophils’ number without compromising their function [66].